JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.38 which represents a decrease of $-0.03 or -2.13% from the prior close of $1.41. The stock opened at $1.41 and touched a low of $1 ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Editas Medicine (NASDAQ:EDIT) Inc. shares have tumbled to a 52-week low, with the stock price touching down at $1.16. According to InvestingPro data, this represents a dramatic ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.